Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
Raises $41 Million To Advance Preclinical Inflammation Programs
10/19/2005 5:12:12 PM
Biolipox AB, a firm developing anti-inflammatory drugs based on its knowledge of arachidonic acid metabolic pathways, disclosed Monday that it raised $41 million in a Series C round led by Scandinavian Life Science Venture.
(FR:N07413) Compound In
Collaboration Enters Phase II
Super Microbe's Life Code Cracked
Drug Companies Launch New Discount Card
Gene "Raises Osteoarthritis Risk"
(DNDN) Cancer Drug Fails To Delay Symptoms;
Falls On Cancer Drug Report
Reaffirms Commitment To Alliance With
Regeneron Pharmaceuticals, Inc.
To Get $50 Million In VEGF Trap Payments
Rats Might Be Multilingual
(AGIX) Provides Update On AGI-1067 Clinical Program; Shares Fall On Delay In Drug Trial
Gene Clue To HIV Origin In Humans
Nereus Pharmaceuticals, Inc.
Closes First Tranche Of $42.6 Million Financing; Company Appoints Three New Directors
comments powered by Disqus.
comments powered by
Academic / Research - Research news
Clinical - Pre-Clinical
Biotech/Pharma - Finance
Biotech/Pharma - Investor
Biotech/Pharma - Finance, Start-Up